Logo En IconLogo Mark IconIcelandic Intellectual Property Office
Plus Black IconMortgagePlus Black IconLicense

SPC335

Samsetning af (a) (R)-1-(2,2-díflúoróbensó[d][1,3]díoxól-5-ýl)-N-(1-(2,3-díhýdroxýprópýl)-6-flúoró-2-(1-hýdroxý-2-metýlprópan-2-ýl)-1H-indól-5-ýl)sýklóprópankarboxamíði eða lyfjafræðilega viðeigandi salti þess og (b) N-(5-hýdroxý-2,4-díert-bútýl-fenýl)-4-oxó-1H-kínólín-3-karboxamíði eða lyfjafræðilega viðeigandi salti þess

  • Status:
    Veitt
  • Application date:
    20.5.2021
  • Application published:
    15.6.2021
  • Grant published:
    15.1.2025
  • Max expiry date:
    5.11.2033
  • Medicine name:
    SYMKEVI
  • Medicine for children:
    No

Timeline

Today
20.5.2021Application
15.6.2021Publication
15.1.2025Registration
5.11.2033Expires

Marketing license

  • IS authorization number:
    EU/1/18/1306/001
  • Date:
    13.11.2018
  • Foreign authorization number:
    EU/1/18/1306
  • Date:
    31.10.2018

Owner

  • Name:
    Vertex Pharmaceuticals Incorporated
  • Address:
    50 Northern Avenue, Boston, MA 02210 US

Agent

  • Name:
    Árnason Faktor ehf.
  • Address:
    Guðríðarstíg 2-4, 113 Reykjavík

Patent

Deadlines

TypeDeadline until

Type: Frestur til að fara yfir drög að vottorði

Deadline until: 27.12.2024

Upload documents